Form 4: Quest Diagnostics SVP Michael Prevoznik Executes Stock Option and Sells Shares

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, exercised stock options and sold shares on August 29, 2024.

Summary

• On August 29, 2024, Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, exercised a non-qualified stock option to acquire 32,551 shares of common stock at a price of $95.795 per share.
• Simultaneously, Prevoznik sold 32,551 shares of common stock at a weighted average price of $154.9727, with individual trades ranging from $154.890 to $155.455.
• Following these transactions, Prevoznik directly owns 38,478 shares of Quest Diagnostics common stock.
• Prevoznik also indirectly owns 5,592 shares through the company's 401(k)/SDCP.

Sentiment

Score: 5

Explanation: Neutral sentiment. The transaction is a routine execution of stock options and subsequent sale, which is a common practice for executives. It doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The exercise of stock options and subsequent sale suggests confidence in the company's prospects, as the executive capitalized on the option's value.

Negatives

• The sale of shares, even after exercising options, could be interpreted as a lack of long-term confidence, although it's a common practice for executives to diversify their holdings.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially leading to short-term price fluctuations.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. It's important to consider these transactions in the context of overall market conditions and company performance.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are common across the healthcare and diagnostics industry.
• Companies like Laboratory Corporation of America (LH) and Bio-Rad Laboratories (BIO) also have executives who regularly exercise options and sell shares.
• The size and frequency of these transactions are generally in line with industry norms for executives at similar levels.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the potential for short-term price fluctuations following the disclosure of the sale.

Key Dates